Recent developments in carbapenems

Expert Opinion on Investigational Drugs

Volumn 11, Issue 4, 2002, Pages 529-544

  Bonfiglio, Giovanni ^a   Russo, Giovanni ^a   Nicoletti, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

lactams; Antibiotics; Carbapenemases; Carbapenems; Serious infections

Indexed keywords

1 OXACEPHEM DERIVATIVE; 3 [(6,7 DIHYDRO 5H PYRROLO[1,2 A]IMIDAZOL 6 YL)THIO] 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 (5 OXO 3 PYRROLIDINYLTHIO) 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; BETA LACTAM ANTIBIOTIC; BETA LACTAM DERIVATIVE; BETA LACTAMASE; BIAPENEM; BMS 181139; CARBAPENEM DERIVATIVE; CARBON; CEPHALOSPORIN DERIVATIVE; CILASTATIN; DORIPENEM; E 1010; ENZYME INHIBITOR; ERTAPENEM; GV 129606; IMIPENEM; KIDNEY ENZYME; LENAPENEM; MEROPENEM; METHYL GROUP; MONOBACTAM DERIVATIVE; PANIPENEM; PENICILLIN DERIVATIVE; SANFETRINEM; SANFETRINEM CILEXETIL; SULFONE; THIENAMYCIN DERIVATIVE; THIOL GROUP; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; AEROMONAS; ANTIBACTERIAL ACTIVITY; BACILLUS CEREUS; BACTERIAL CHROMOSOME; BACTEROIDES FRAGILIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SAFETY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG USE; ENTEROBACTERIACEAE; ENZYME ISOLATION; FLAVOBACTERIUM; GENETIC CODE; HOSPITAL INFECTION; HUMAN; INFECTION; KLEBSIELLA PNEUMONIAE; LEGIONELLA; NEPHROTOXICITY; NONHUMAN; PLASMID; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA MARCESCENS; SIDE EFFECT; STENOTROPHOMONAS MALTOPHILIA; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

BACTERIAL INFECTIONS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CARRIER PROTEINS; DRUG RESISTANCE, BACTERIAL; HEXOSYLTRANSFERASES; HUMANS; MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE; PENICILLIN-BINDING PROTEINS; PEPTIDYL TRANSFERASES;

EID: 0036241139     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.4.529     Document Type: Review

References (149)

1. Thienamycin, a new β-lactam antibiotic: I. Discovery, taxonomy, isolation and physical properties
2. Thienamycin: Development of imipenem-cilastatin
3. Structure and absolute configuration of thienamycin
4. The carbapenem family
5. Olivanic acids, a family of β-lactam antibiotics with β-lactamase inhibitory properties produced by Streptomyces sp. II. Isolation and characterisation of MM 4550, MM 17880
6. Comparative antibacterial properties in vitro of seven olivanic acid derivatives-MM 4550, MM 13902, MM17880, MM 22380, MM 22381, MM 22382 and MM 22383
7. Asparenomycin A, a new carbapenem antibiotic
8. The structure of pluracidomycins, new carbapenem antibiotics
9. A novel β-lactamase inhibitor, SF-2103A, produced by a Streptomyces
10. Novel carbapenem derivative SF2103A: Studies on the mode of β-lactamase inactivation
11. Carpetimycin A e B, new β-lactam antibiotics
12. PS-6 and PS-7, new β-lactam antibiotics. Isolation physiochemical properties and structures
13. PS-8, a minor carbapenem antibiotic
14. SQ 27860, a simple carbapenem produced by species of Serratia and Erwinia
15. In vitro and pharmacokinetic properties of the carbapenems
16. MK0787 (N-formimidoyl thienamycin): Evaluation of in vitro and in vivo activities
17. Imipenem: First of a new class of antibiotic
18. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I
19. Carbapenems, a new class of β-lactam antibiotics. Discovery and development of imipenem/cilastatin
20. Thienamycin: Development of imipenem-cilastatin
21. Nephroprotective effect and its mechanism of betamipron (2)-Relationships of renal excretion
22. In vitro dehydropeptidase-1 activity and its hydrolytic activity of panipenem in several tissue in animal species and their influence on the disposition of panipenem in vivo
23. Synthetic carbapenem antibiotics. I. 1-β-methylcarbapenem
24. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase
25. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase-I
26. Radiolabeled quaternary carbapenems and their interactions with human serum albumin
27. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex
28. In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I
29. Renal dehydropeptidase-I stability of LJC-10,627, a new carbapenem antibiotic
30. In vitro activity and pharmacokinetic evaluation of a novel long acting carbapenem antibiotic, MK-826 (L-748,345)
31. In vitro activity of a new carbapenem antibiotic, BO2727, with potent antipseudomonal activity
32. A novel 1β-methylcarbapenem antibiotic, S-4661: Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1β-methylcarbapenems
33. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity
34. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem
35. In vitro activity of the tribactam GV104326 against Gram-positive, Gram-negative and anaerobic bacteria
36. DZ-2660, a new oral carbapenem antibiotic, 1 :Structure activity relationships and in vitro activity
37. Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia coli K-12
38. Properties of penicillin-binding proteins of Escherichia coli K-12
39. Escherichia coli resistance to β-lactam antibiotics through a decresed in the affinity of a target for lethality
40. Biochemical comparison of imipenem, meropenem and biapenem: Permeability, binding to penicillin-binding proteins and stability to hydrolysis by β-lactamases
41. Comparison of two carbapenems, SM-7338 and imipenem: Affinities for penicillin-binding proteins and morphological changes
42. Antibacterial properties of BO-2727, a new carbapenem antibiotic
43. Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2
44. Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus
45. Asparenomycins A, B and C, new carbapenems antibiotics. V. Inhibition of β-lactamases
46. Inhibition of RTEM β-lactamase from Escherichia coli. Interactions with derivatives of olivanic acids
47. Antimicrobial and β-lactamases activities of carpetimycins A and B, new carbapenem antibiotics
48. 2, new carbapenem antibiotics. IV. Inhibitory activity against β-lactamases
49. PS-5 inhibition of a β-lactamase from Proteus vulgaris
50. The semi-synthetic thienamicin derivative MK-0787 and its properties with respect to a range of β-lactamases from clinically important bacterial species
51. Cefoxitin, N-formimidoyl thienamycin, clavulanic acid and penicillanic sulfone as suicide inhibitors for different types of β-lactamases produced by Gram-negative bacteria
52. Imipenem as substrate and inhibitor of β-lactamases
53. Beta-lactamase stability of imipenem
54. Interactions of meropenem, with β-lactamases, including enzymes with extended spectrum activity against third generation cephalosporins
55. Meropenem: Activity against resistant Gram-negative bacteria and interactions with β-lactamases
56. Interactions of biapenem with active-site serine and metallo-β-lactamases
57. A functional classification scheme for β-lactamases and its correlation with molecular structure
58. Beta-lactamases and bacterial resistance to antibiotics
59. Metallo-β-lactamases: A class apart
60. β-Lactamases in laboratory and clinical resistance
61. Carbapenem-hydrolyzing β-lactamases
62. The structure of β-lactamases
63. Resistance caused by decreased penetration of β-lactam antibiotics into Enterobacter cloacae
64. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain
65. Carbapenemases
66. An overview of the kinetic parameters of class B β-lactamases
67. Purification and properties of inducible penicillin β-lactamase isolated from Pseudomonas maltophilia
68. The production and molecular properties of the zinc β-lactamase from Pseudomonas maltophilia IID 1275
69. Purification and characterization of inducible β-lactamases in Aeromonas spp
70. Biochemical properties of β-lactamase produced by Legionella gormanii
71. Biochemical properties of β-lactamases produced by Flavobacterium odoratum
72. Molecular characterization of a carbapenem-hydrolyzing beta-lactamase from Chryseobacterium (Flavobacterium) indologenes
73. Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing β-lactamases in Chryseobacterium meningosepticum
74. β-Lactamase-mediated imipenem resistance in Bacteroides fragilis
75. Metallo-β-Lactamase Producers in Environmental Microbiota: New Molecular Class B Enzyme in Janthinobacterium lividum
76. Transferable imipenem resistance in Pseudomonas aeruginosa
77. Appearance of IMP-1 metallo-beta-lactamase in Europe
78. VIM, a new integronborne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate
79. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France
80. Molecular heterogeneity of bla(VIM-2)-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-beta-lactamase
81. Molecular characterization of an enterobacterial metallo-β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance
82. Carbapenem-hydrolyzing IMP-1 β-lactamase in Klebsiella pneumoniae from Singapore
83. Characterization of the metallo-β-lactamase determinant of Acinetobacter baumannii AC-54/97 reveals the existence of bla(IMP) allele variants carried by gene cassettes of different phylogeny
84. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae
85. Standard numbering scheme for Class B β-lactamases
86. Plasmid-mediated dissemination of the metallo-β-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens
87. Resistance to imipenem in Pseudomonas aeruginosa: Clinical observations and biochemical mechanism
88. Decreased outer membrane permeability in imipenem-resistant mutants in Pseudomonas aeruginosa
89. Outer membrane protein D2 channel catalyses facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa
90. Role of OmpD2 and chromosomal β-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa
91. Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides
92. Meropenem resistance in Pseudomonas aeruginosa
93. In vitro activity of biapenem against recent clinical isolates
94. Overview of a new carbapenem, panipenem/betamipron
95. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem
96. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa
97. Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa
98. Assignment of the substrate-selective subunits of the MexE-MexF-OprN multidrug efflux pump of Pseudomonas aeruginosa
99. Characterization of the MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa
100. The carbapenems: New broad spectrum β-lactam antibiotics
101. In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae
102. In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem
103. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterised resistance mechanisms
104. Meropenem: A microbiological overview
105. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide
106. MYSTIC (meropenem yearly susceptibility test information collection): A global overview
107. In vitro antibacterial activity and β-lactamase stability of a new carbapenem, BO-2727
108. Laboratory data which differentiate meropenem and imipenem
109. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa
110. Antibiotic resistance in Pseudomonas aeruginosa. An Italian survey
111. Mechanisms of β-lactam resistance in Italian isolates of Pseudomonas aeruginosa
112. MYSTIC (meropenem yearly susceptibility test information collection) results from the Americas: Resistance implications in the treatment of serious infections
113. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Europe: Comparison of antibiotic susceptibilities between countries and centre types
114. Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-β-methyl carbapenem
115. In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem
116. In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins
117. Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect and against staphylococci
118. Meropenem a new carbapenem antibiotic
119. Tyrrel K.L. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections
120. The in vitro activity of L-627 against anaerobic bacteria
121. In vitro activity of R-95867, the active metabolite of a new oral carbapenem. CS-834, against anaerobic bacteria
122. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem and quinupristin-dalfopristin) against Bacteroides fragilis group: Comparison with the activities of 14 other agents
123. In vitro and in vivo antibacterial activities of GV129606, a new broad spectrum trinem
124. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalised patients
125. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
126. Empirical monotherapy with meropenem in serious bacterial infections
127. Imipenem as monotherapy in the treatment of intensive care patients with severe infections
128. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America
129. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: A review
130. Empiric monotherapy for febrile neutropenia - A randomised study comparing meropenem with ceftazidime
131. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients
132. Management of febrile episodes in neutropenic patients
133. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients, a comparison of meropenem and imipenem/cilastatin: COPD Study Group
134. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategy
135. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomised study: Meropenem Lower Respiratory Infection Group
136. Pneumonia: The impact of risk factors on the outcome of treatment with meropenem and ceftazidime
137. Carbapenems in clinical practice: A guide to their use in serious infection
138. Imipenem versus tobramycin-antianaerobe antibiotic therapy in intraabdominal infections
139. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intraabdominal infections
140. Imipenem therapy for perforated and gangrenous appendicitis
141. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: Report from Swedish study group
142. Meropenem versus tobramycin plus clindamycin for treatment of intrabdominal infections: Results of a prospective, randomised, double-bind clinical trial
143. Meropenem in the treatment of intra-abdominal infection: Review of the clinical trials
144. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections
145. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intraabdominal infections
146. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infetions requiring surgery
147. Selecting therapy for serious infections in children: Maximizing safety and efficacy
148. A randomised comparison of meropenem with cefotaxime for the treatment of bacterial meningitis
149. Carbapenems: The pinnacle of the β-lactam antibiotics or room for improvement?